Valuation: SurModics

Market Cap 427M 374M 348M 319M 602M 41.24B 611M 4.14B 1.62B 20.18B 1.6B 1.57B 69.71B P/E 2023
-292x
P/E 2024 -47.3x
Enterprise Value 420M 368M 342M 314M 592M 40.57B 601M 4.07B 1.59B 19.85B 1.58B 1.54B 68.59B EV / Sales 2023
3.33x
EV / Sales 2024 4.33x
Free-Float
99.63%
Yield 2023 *
-
Yield 2024 -
1 year 25.87
Extreme 25.87
43
3 years 25.17
Extreme 25.17
43
5 years 16
Extreme 16
62.27
10 years 16
Extreme 16
82.35
Manager TitleAgeSince
Chief Executive Officer 67 18/11/2025
Director of Finance/CFO 53 18/11/2025
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 67 18/11/2025
Director/Board Member 53 18/11/2025
Date Insider Type Main position Quantity % Market Cap.
19/11/25 Issuer sale

Chairman

61,368 0.4292%
19/11/25 Issuer sale

Chief Financial Officer

184,019 1.2871%
19/11/25 Issuer sale

Executive/Senior Manager

152,074 1.0636%
Change 5-day change 1-year change 3-year change Capi.($)
+0.35%-.--%+34.71%+34.95% 615M
+0.90%+12.66%-20.01%-12.00% 174B
-0.56%+1.76%-10.65%-7.95% 105B
-0.82%+1.35%+2.60%+56.07% 58.97B
-1.42%-1.44%+32.81%+55.58% 52.24B
-0.44%-1.11%-15.51%-42.17% 42.39B
-4.89%-5.73% - - 33.05B
-4.44%-1.79%-16.08%-45.31% 28.84B
-0.23%-0.16%+63.73%-5.01% 25.38B
-0.56%-0.42%-5.87%-9.27% 20.64B
Average -1.01%+0.56%+7.30%+2.76% 54.11B
Weighted average by Cap. -0.25%+3.86%-4.59%-0.20%

Financials

2023 2024
Net sales 133M 116M 108M 99.1M 187M 12.79B 189M 1.28B 503M 6.26B 498M 487M 21.63B 126M 110M 103M 94.24M 178M 12.17B 180M 1.22B 478M 5.95B 473M 463M 20.56B
Net income -1.54M -1.35M -1.25M -1.15M -2.16M -148M -2.2M -14.88M -5.83M -72.52M -5.77M -5.64M -251M -11.54M -10.11M -9.39M -8.63M -16.26M -1.11B -16.5M -112M -43.78M -545M -43.33M -42.39M -1.88B
Net Debt -12.1M -10.6M -9.84M -9.05M -17.04M -1.17B -17.29M -117M -45.9M -571M -45.43M -44.45M -1.97B -6.87M -6.02M -5.59M -5.14M -9.68M -663M -9.82M -66.57M -26.06M -324M -25.79M -25.23M -1.12B
Logo SurModics
Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
Employees
389
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. SRDX Stock